Patents Assigned to Somerset Pharmaceuticals, Inc.
  • Methods for preventing photodamaged skin by administering selegiline or desmethylselegiline
    Patent number: 7147864
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: December 12, 2006
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • S(+) Desmethylselegiline and its use to treat ADHD
    Patent number: 6759053
    Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: July 6, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto
  • Method for preventing and treating peripheral neuropathy by administering selegiline
    Patent number: 6743824
    Abstract: The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: June 1, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: George Bobotas
  • Methods for treating photodamaged skin by administering selegiline or desmethylselegiline
    Patent number: 6709664
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: March 23, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • Methods for treating multiple sclerosis employing desmethylselegiline
    Patent number: 6699495
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 2, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
    Patent number: 6562364
    Abstract: The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: May 13, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Anthony R. DiSanto, Cheryl D. Blume
  • Methods employing R(?)-desmethylselegiline
    Patent number: 6562365
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: May 13, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • Method for preventing and treating peripheral neuropathy by administering selegiline
    Patent number: 6538036
    Abstract: The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: March 25, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: George Bobotas
  • Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
    Patent number: 6528082
    Abstract: The application is directed to the treatment of neoplastic diseases or conditions by administering R(−) desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. Neoplastic diseases and conditions responsive to R(−) desmethylselegiline and/or S(+) desmethylselegiline include both malignant and benign neoplasms.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: March 4, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • Method for preventing and treating peripheral neuropathy by administering selegiline
    Patent number: 6500868
    Abstract: A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: December 31, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: George Bobotas
  • Method for treating wounds, burns and dermatological damage by administering selegiline or desmethylselegiline
    Patent number: 6461619
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: October 8, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • S(+) desmethylselegiline and its use to treat immune system dysfunction
    Patent number: 6455060
    Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: September 24, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto
  • S(+) desmethylselegiline and drug withdrawal
    Patent number: 6420433
    Abstract: The present invention provides novel compositions and methods for using the S-(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.0015 mg/kg of body weight.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: July 16, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto
  • R(-)desmethylselegiline and its use in transdermal delivery compositions
    Patent number: 6419948
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 16, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • S(+) desmethylselegiline and its use in transdermal delivery compositions
    Patent number: 6375979
    Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: April 23, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto
  • Methods and pharmaceutical compositions employing desmethylselegiline
    Patent number: 6348208
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: July 12, 1996
    Date of Patent: February 19, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
    Patent number: 6319954
    Abstract: The present invention provides novel compositions and methods for using the S-(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.0015 mg/kg of body weight.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: November 20, 2001
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto
  • Methods and pharmaceutical compositions employing desmethylselegiline
    Patent number: 6299901
    Abstract: The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: October 9, 2001
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Anthony R. DiSanto, Cheryl D. Blume
  • Method for preventing and treating peripheral neurophathy by administering selegiline
    Patent number: 6239181
    Abstract: The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: May 29, 2001
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: George Bobotas
  • S (+) Desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
    Patent number: 6210706
    Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: April 3, 2001
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Anthony R. DiSanto